SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thean who wrote (28)10/28/1996 3:39:00 PM
From: Bob Ponko   of 965
 
I suppose the 6 month data are fairly positive, although I notice they had to combine endpoints to get statistically meaningful results.
The stock is down, so I guess more people are viewing the results as negative.
By the way, someone commented earlier that insurers won't pay for REOPRO except when used for FDA indications. With DRGs, hospitals are not paid separately for injectable meds. Insurers pay one DRG for the diagnosis necessitating hospitalization. The cost of the drug is eaten by the hospital.
The dilemma hopital P & T committees are finding with REOPRO, is how to buy this expensive drug with limited hospital pharmacy budgets.
Obviously hospitals have to give in when the clinical evidence is very strong, such as with Epogen or TPA. As clincal data mount to support the use of REOPRO, P & T committees will approve its purchase, and sales will skyrocket.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News